COMPOSITIONS AND METHODS FOR PREVENTING OR REDUCING POSTOPERATIVE ILEUS AND GASTRIC STASIS IN MAMMALS

• US 20070286892A1
• Filed: 06/12/2007
• Published: 12/13/2007
• Est. Priority Date: 06/13/2006
• Status: Abandoned Application

• Current Assignee: Ethicon Incorporated (Johnson & Johnson)
• Original Assignee: Ethicon Incorporated (Johnson & Johnson)
• Inventors: Cooper, Kevin, Herzberg, Uri, Wadsworth, Scott
• Application Number:
  US11/761,726
• Publication Number:
  US 20070286892A1
• Time in Patent Office: Days
• US Class Current: 424/443
• CPC Class Codes: A61K 31/165 having aromatic rings, e.g. colchicine, atenolol, progabide
• CPC Class Codes: A61K 31/519 ortho- or peri-condensed with heterocyclic rings
• CPC Class Codes: A61K 47/02 Inorganic compounds
• CPC Class Codes: A61K 47/38 Cellulose; Derivatives thereof

Abstract

Disclosed are compositions and methods for preventing or reducing postoperative ileus and gastric stasis. Such compositions include a combination of a carrier component and a bioactive component which acts to prevent or reduce post-poperative ileus. Such methods include administering a therapeutically effective amount of the composition directly to the serosal surfaces of the gastrointestinal and other visceral organs.

Claims

1. A composition for application to intestinal and other visceral serosal surfaces to prevent or reduce postoperative ileus and gastric stasis, which composition comprises a carrier component and a bioactive component.

2. The composition of claim 1 wherein said bioactive component comprises a mast cell degranulation inhibitor selected from the group consisting of Tranilast, derivatives of Tranilast, analogs of Tranilast, Pemirolast, derivatives of Pemirolast, analogs of Pemirolast and combinations thereof.

3. The composition of claim 2 wherein said derivatives of Tranilast and analogs of Tranilast are selected from the group consisting of N-(2-Acetyl-4,5dimethoxyphenyl)(4-((phenylamino)carbonylamino)phenyl)formamide, N-(2 Acetyl-4,5-dimethoxyphenyl)-2-(4-((phenylamino) carbonylamino)phenyl)ethanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-;

((phenylamino)-carbonylamino)phenyl)prop-2-enamide, N-(2-Acetyl-4,5 dimethoxyphenyl)-3-(4-((phenylamino)-carbonylamino)phenyl)propanamide, N (2-Acetyl-4,5-dimethoxyphenyl)-4-(4 ((phenylamino)carbonylamino)phenyl)butanamide, N-(2-Acetyl-4,5dimethoxyphenyl)-3-(4-(phenylcarbonylamino) carbonylamino)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(2 phenylacetylamino)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3 (4-(phenoxycarbonylamino)phenyl)propanamide, N-(2-Acetyl-4,5dimethoxyphenyl)-3-(4-(((2 nitrophenyl)amino)carbonylamino)phenyl)propanamide, N-(2-Acetyl-4,5dimethoxyphenyl)-3-(4-(((3 nitrophenyl)amino) carbonylamino)phenyl)propanamide, N-(2-Acetyl-4,5dimethoxyphenyl)-3-(4-(((4 nitrophenyl)amino)carbonylamino)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(((2 aminophenyl)amino)carbonylamino)phenyl)propanamide, N-(2-Acetyl-4,5-1 dimethoxyphenyl)-3-(4-(((3-1 S aminophenyl)amino)carbonylamino)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(((4-aminophenyl)amino)carbonylamino)phenyl) propanamide, N-(2-Acetyl-4, 5-dimethoxyphenyl)-3-(4-(((4-fluorophenyl)amino)carbonylamino)phenyl)propanamide, N-(2-Acetyl-4,5dimethoxyphenyl)-3-(4-(((4-acetylphenyl)amino)carbonylamino)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(((4-methylphenyl)amino)carbonylamino) phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(((4 methoxyphenyl)amino)carbonylamino)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(((3,4,5-trimethoxyphenyl)amino)carbonylamino) phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(((4-pyridyl)amino)carbonylamino)phenyl)propanamide, N-(2-Acetyl-4,5-d imethoxyphenyl)-3-(4((benzylamino)carbonylamino)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-((butyl amino)carbonylamino)phenyl)propanamide N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-((cyclohexylamino)carbonylamino)phenyl)propanamide and combinations thereof.

4. The composition of claim 2 wherein said derivatives of Pemirolast and analogs of Pemirolast are selected from the group consisting of 3-(1 H-Tetrazol-5-yl)-4H pyridol[1,2-a]pyrimidin-4-one, 7-Methyl-3-(1H-Tetrazol-5-yl)-4H-pyridol[1,2oc]pyrimidin-4-one, 8-Methyl-3-(1H-Tetrazol-5-yl)-4H-pyridol[1,2-oc]pyrimidin-4 one, 7-Ethyl-3-(1 H-Tetrazol-5-yl)-4H-pyridol[1,2-oc]pyrimidin-4-one, 7-n-Butyl-3 (1 H-Tetrazol-5-yl)-4H-pyridol[1,2-oc]pyrimidin-4-one, 7-Phenyl-3-(1H-Tetrazol-5-:

yl)-4H-pyridol[1,2-oc]pyrimidin-4-one, 7-Chloro-3-(1 H-Tetrazol-5-yl)-4H-;

pyridol[1,2-oc]pyrimidin-4-one, 7,9-dimethyl-3-(1 H-Tetrazol-5-yl)-4H-pyridol[1,2a]pyrimidin-4-one, 9-Ethyl-3-(1H-Tetrazol-5-yl)-4H-pyridol[1,2-oc]pyrimidin-4 one, 8,9,1-,1 1-tetrahydro-3-(1H-Tetrazol-5-yl)-4H-pyrimido[2,1-oc]isoquinol-4 one and combinations thereof.

5. The composition of claim 2 wherein said mast cell degranulation inhibitor is selected from the group consisting of Tranilast, Pemirolast and combinations thereof.

6. The composition of claim 1 wherein the carrier component is in a form selected from the group consisting of an injectable gel, a sprayable gel, injectable liquid, a sprayable liquid, microparticles, beads, a mesh, a weave, a knit, and a nonwoven.

7. The composition of claim 6 wherein said injectable gel, sprayable gel, injectable liquid, sprayable liquid comprises an aqueous solvent and a gelling material.

8. The composition of claim 7 wherein said aqueous solvent is selected from the group consisting of physiological buffer solution, saline and water.

9. The composition of claim 7 wherein said aqueous solvent is selected from the group consisting of buffered saline, hypertonic saline, phosphate buffer solution, hypertonic buffer, Hank'"'"'s balanced salts solution, Tris buffered saline, Hepes buffered saline and combinations thereof.

10. The composition of claim 7 wherein said gelling material is selected from the group consisting of collagen, elastin, thrombin, fibronectin, gelatin, fibrin, tropoelastin, polypeptides, laminin, proteoglycans, fibrin glue, fibrin clot, platelet rich plasma (PRP) clot, platelet poor plasma (PPP) clot, self-assembling peptide hydrogels, atelocollagen, starch, pectin, cellulose, alkyl cellulose, alkylhydroxyalkyl cellulose, hydroxyalkyl cellulose, cellulose sulfate, salts of carboxymethyl cellulose, carboxymethyl cellulose, carboxyethyl cellulose, chitin, carboxymethyl chitin, hyaluronic acid, salts of hyaluronic acid, alginate, cross-linked alginate alginic acid, propylene glycol alginate, glycogen, dextran, dextran sulfate, curdlan, pectin, pullulan, xanthan, chondroitin, chondroitin sulfates, carboxymethyl dextran, carboxymethyl chitosan, chitosan, heparin, heparin sulfate, heparan, heparan sulfate, dermatan sulfate, keratan sulfate, carrageenans, chitosan, starch, amylose, amylopectin, poly-N-glucosamine, polymannuronic acid, polyglucuronic acid, polyguluronicacid, ribonucleic acids, deoxyribonucleic acids, poly(N-isopropylacrylamide), poly(oxyalkylene), copolymers of poly(ethylene oxide)-poly(propylene oxide), poly(vinyl alcohol), polyacrylate, monostearoyl glycerol co-Succinate/polyethylene glycol (MGSA/PEG) copolymers and combinations thereof.

11. The composition of claim 10 wherein said gelling material is selected from the group consisting of starch, pectin, cellulose, alkyl cellulose, alkylhydroxyalkyl cellulose, hydroxyalkyl cellulose, cellulose sulfate, salts of carboxymethyl cellulose, carboxymethyl cellulose, carboxyethyl cellulose, chitin, carboxymethyl chitin, hyaluronic acid, salts of hyaluronic acid, alginate, cross-linked alginate alginic acid, propylene glycol alginate, glycogen, dextran, dextran sulfate, curdlan, pectin, pullulan, xanthan, chondroitin, chondroitin sulfates, carboxymethyl dextran, carboxymethyl chitosan, chitosan, heparin, heparin sulfate, heparan, heparan sulfate, dermatan sulfate, keratan sulfate, carrageenans, chitosan, starch, amylose, amylopectin, poly-N-glucosamine, polymannuronic acid, polyglucuronic acid, polyguluronicacid and combinations thereof.

12. The composition of claim 11 wherein said gelling material is selected from the group consisting of salts of carboxymethyl cellulose, carboxymethyl cellulose, carboxyethyl cellulose, hyaluronic acid, salts of hyaluronic acid, alginate, cross-linked alginate and combinations thereof.

13. The composition of claim 12 wherein said gelling material comprises salts of carboxymethyl cellulose wherein said salts of carboxymethyl cellulose is sodium carboxymethyl cellulose.

14. The composition of claim 6 wherein said microparticles, beads, a mesh, a weave, a knit, and a nonwoven comprises oxidized regenerated cellulose.

15. The composition of claim 1 wherein said carrier component comprises an injectable gel comprising phosphate buffered saline and sodium carboxymethyl cellulose;

and wherein said bioactive component comprises Tranilast.

16. The composition of claim 1 wherein said carrier component comprises a mesh comprising oxidized regenerated cellulose;

and wherein said bioactive component is Tranilast.

17. A method of preventing or reducing postoperative ileus and gastric stasis, which method comprises administering directly to serosal surfaces of gastrointestinal and other visceral organs a therapeutically effective amount of a composition which comprises a carrier component and a bioactive component.

18. The method according to claim 17 wherein the bioactive component comprises a mast cell degranulation inhibitor selected from the group consisting of Tranilast, derivatives of Tranilast, analogs of Tranilast, Pemirolast, derivatives of Pemirolast, analogs of Pemirolast and combinations thereof.

19. The method of claim 17 wherein the composition is in a form selected from the group consisting of a porous foam, an injectable gel, a sprayable gel, injectable liquid, sprayable liquid, microparticles, beads, an implantable device, a mesh, a weave, a knit, and a nonwoven.

20. The method of claim 19 wherein said injectable gel, sprayable gel, injectable liquid, sprayable liquid comprises an aqueous solvent and a gelling material.

21. The method of claim 20 wherein said aqueous solvent is selected from the group consisting of physiological buffer solution, saline and water.

22. The method of claim 20 wherein said aqueous solvent is selected from buffered saline, hypertonic saline, phosphate buffer solution, hypertonic buffer, Hank'"'"'s balanced salts solution, Tris buffered saline, Hepes buffered saline and combinations thereof.

23. The method of claim 20 wherein said gelling material is selected from the group consisting of salts of carboxymethyl cellulose, carboxymethyl cellulose, carboxyethyl cellulose, hyaluronic acid, salts of hyaluronic acid, alginate, cross-linked alginate and combinations thereof.

24. The method of claim 23 wherein said gelling material comprises salts of carboxymethyl cellulose wherein said salts of carboxymethyl cellulose is sodium carboxymethyl cellulose.

25. The method of claim 19 wherein said microparticles, beads, a mesh, a weave, a knit, and a nonwoven comprises oxidized regenerated cellulose.

26. The method of claim 17 wherein said carrier component comprises an injectable gel comprising phosphate buffered saline and sodium carboxymethyl cellulose;

and wherein said bioactive component is Tranilast.

27. The method of claim 17 wherein said carrier component comprises a mesh comprising oxidized regenerated cellulose;

and wherein said bioactive component is Tranilast.